Total Payments
$1.3M
2024 Payments
$244,434
Companies
67
Transactions
2,751
Medicare Patients
6,775
Medicare Billing
$842,094
Payment Breakdown by Category
Other$973,097 (74.5%)
Travel$254,951 (19.5%)
Food & Beverage$54,070 (4.1%)
Consulting$23,333 (1.8%)
Education$115.20 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $972,110 | 649 | 74.5% |
| Travel and Lodging | $254,951 | 389 | 19.5% |
| Food and Beverage | $54,070 | 1,692 | 4.1% |
| Consulting Fee | $23,333 | 11 | 1.8% |
| Honoraria | $987.50 | 2 | 0.1% |
| Education | $115.20 | 7 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $515,012 | 907 | $0 (2024) |
| Novo Nordisk Inc | $460,632 | 634 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $188,733 | 279 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $63,225 | 190 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $45,112 | 119 | $0 (2024) |
| ABBVIE INC. | $14,759 | 81 | $0 (2024) |
| Mannkind Corporation | $4,937 | 56 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $1,690 | 63 | $0 (2024) |
| Allergan Inc. | $1,524 | 7 | $0 (2019) |
| Corcept Therapeutics | $1,289 | 51 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $244,434 | 353 | SANOFI-AVENTIS U.S. LLC ($117,098) |
| 2023 | $132,811 | 300 | Lilly USA, LLC ($107,339) |
| 2022 | $188,626 | 400 | Lilly USA, LLC ($98,626) |
| 2021 | $146,450 | 379 | Novo Nordisk Inc ($88,699) |
| 2020 | $98,147 | 201 | Lilly USA, LLC ($52,087) |
| 2019 | $144,098 | 350 | Novo Nordisk Inc ($74,810) |
| 2018 | $151,344 | 355 | Novo Nordisk Inc ($69,054) |
| 2017 | $199,717 | 413 | Novo Nordisk Inc ($94,207) |
All Payment Transactions
2,751 individual payment records from CMS Open Payments — Page 1 of 111
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Diabetes Care | ||||||
| 12/24/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Diabetes Care | ||||||
| 12/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $9.79 | General |
| Category: Obesity | ||||||
| 12/17/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Bone Health | ||||||
| 12/16/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/02/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Cardio-renal | ||||||
| 11/22/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $21.56 | General |
| 11/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $2.03 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,820.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $1,401.46 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/13/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/12/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/08/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,738.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $750.75 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $412.90 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,883 | 4,079 | $592,302 | $246,703 |
| 2022 | 9 | 1,595 | 3,138 | $484,644 | $207,244 |
| 2021 | 11 | 1,686 | 3,335 | $521,084 | $225,586 |
| 2020 | 10 | 1,611 | 2,453 | $465,611 | $162,561 |
Total Patients
6,775
Total Services
13,005
Medicare Billing
$842,094
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 521 | 1,041 | $257,127 | $110,756 | 43.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 292 | 530 | $175,960 | $78,991 | 44.9% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 50 | 236 | $32,804 | $11,249 | 34.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 50 | 226 | $24,408 | $9,921 | 40.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 102 | 230 | $18,630 | $6,778 | 36.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $16,082 | $6,259 | 38.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 322 | 631 | $25,240 | $5,922 | 23.5% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 36 | 133 | $11,172 | $4,680 | 41.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $10,933 | $3,859 | 35.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 372 | 896 | $6,272 | $2,840 | 45.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 18 | 19 | $5,700 | $2,044 | 35.9% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 17 | 33 | $4,488 | $1,789 | 39.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 14 | $2,352 | $1,134 | 48.2% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 27 | 27 | $1,134 | $478.14 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 479 | 913 | $225,511 | $97,262 | 43.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 288 | 541 | $179,612 | $82,704 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $18,920 | $7,014 | 37.1% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 294 | 572 | $22,880 | $5,458 | 23.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 73 | 169 | $13,689 | $5,095 | 37.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 37 | 39 | $11,700 | $4,183 | 35.8% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 352 | 820 | $5,740 | $2,633 | 45.9% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2022 | 15 | 25 | $3,400 | $1,473 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 19 | $3,192 | $1,422 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 455 | 894 | $220,818 | $98,749 | 44.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 305 | 603 | $200,196 | $90,944 | 45.4% |
About Dr. Daniel Gozzi, MD
Dr. Daniel Gozzi, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Suitland, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316931413.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Gozzi, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $244,434 received in 2024. These payments were reported across 2,751 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($972,110).
As a Medicare-enrolled provider, Gozzi has provided services to 6,775 Medicare beneficiaries, totaling 13,005 services with total Medicare billing of $842,094. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Suitland, MD
- Active Since 09/02/2005
- Last Updated 03/01/2011
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1316931413
Products in Payments
- MOUNJARO (Drug) $231,561
- Ozempic (Drug) $152,032
- TZIELD (Biological) $124,494
- Tresiba (Drug) $86,989
- TRULICITY (Drug) $80,496
- HUMULIN (Drug) $77,031
- RYBELSUS (Drug) $77,026
- JARDIANCE (Drug) $76,467
- Rybelsus (Drug) $59,946
- FARXIGA (Drug) $48,864
- Victoza (Drug) $41,999
- Xultophy 100/3.6 (Drug) $25,212
- SOLIQUA (Drug) $24,046
- BASAGLAR (Drug) $15,629
- BYDUREON (Drug) $14,361
- TOUJEO (Drug) $13,778
- SOLIQUA 100/33 (Drug) $11,925
- SOLIQUA 100/33 (Biological) $8,919
- SYNTHROID (Drug) $6,484
- AFREZZA (Drug) $4,937
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.